Astrazeneca plc
NASDAQ: AZN
$78.90
+$0.32 (+0.4%)
Closing Price on September 19, 2024
AZN Articles
We noted earlier today that AstraZeneca plc (NYSE: AZN) had lost a patent ruling and that the company’s anti-pyschotic drug Seroquel lost its patent protection today. That’s all it took for Teva...
Published:
Last Updated:
Late last Friday, drug maker AstraZeneca PLC (NYSE: AZN) lost its court fight to prevent a generic version of its anti-psychotic drug Seroquel from reaching the US market. The company had sought to...
Published:
Drug developer Targacept Inc. (NASDAQ: TRGT) and partner AstraZeneca plc (NYSE: AZN) today announced that they will not file for regulatory approval on an anti-depressant drug called TC-5214...
Published:
US equity markets opened lower this morning, but after the first hour or so of trading, the three major indexes moved to positive territory where they remained for the rest of the day. There was talk...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Tuesday morning. AON Corporation (NYSE: AON) Cut to Neutral at...
Published:
Last Updated:
Today is Facebook Day. It will be remembered that way as long as there are IPOs. The Facebook public offering has every aspect of what makes IPOs the focus of so much interest. No large medium in...
Published:
Dendreon (NASDAQ: DNDN) soared almost 40% in value, or $3.02 a share, in active trading on Thursday after announcing that fourth-quarter revenue from its Provenge prostate-cancer vaccine would exceed...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Thursday morning. AstraZeneca PLC (NYSE: AZN) Cut to...
Published:
Last Updated:
Layoffs were part of the business news yesterday. Enough people lost jobs in a series of three “downsizings” to reminds those who believe unemployment continues to fall that the economy still...
Published:
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie business, a drug company tries to develop that...
Published:
Equities started the day with a solid move up, but lost momentum after about half an hour. The downward move lasted into the late morning, at which time stocks started a fitful climb back up. There...
Published:
Last Updated:
These are some of Tuesday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls. Aixtron SE (NASDAQ: AIXG) Raised to Equalweight at Morgan Stanley. Alcatel-Lucent...
Published:
Sales for the big pharmaceutical companies are expected to be hit by pricing pressure in Europe, a lack of urgent new on the coming flu season, lower rates of prescription writing, and more...
Published:
Last Updated: